Shinro Tashiro

EPS Holdings, Inc. engages in the drug development business. It operates through the following segments: Contract Research Organization (CRO), Site Management Organization (SMO), Contract Sales Organization (CSO), Global Research, Ekishin, and Others. The CRO segment offers clinical trials, data management, and statistical analysis. The SMO segment enters into contracts with medical institutions to conduct clinical trials. The CSO segment provides drug information and awareness for medical and pharmaceutical industries. The Global Research segment provides consignment services through its subsidiary for multilateral clinical trials in Asia-Pacific. The Ekishin segment focuses on medical equipment, pharmaceutical and investment related businesses through its Japan and China based subsidiaries. The Others segment provides various services related to management of clinical research from business processing outsource business related to medicine and medical care. The company was founded on May 30, 1991 and is headquartered in Tokyo, Japan.

EP-SOGO Co., Ltd. operates as a Site Management Organization and provides clinical testing services. It supports the doctors and nurses in conducting clinical trials. The company was founded on December 24, 1999 and is headquartered in Tokyo, Japan.

EP-PharmaLine Co., Ltd. provides recruitment, training, and support services to the medical and healthcare industries. It offers contract sales organization, drug information services, business process outsourcing, and medical equipment support services. The firm also provides support services including medical call center, healthcare, post marketing surveillance, pharmaceutical distribution management, emergency key management center, and convention support services. The company was founded in October 2013 and is headquartered in Tokyo, Japan.